Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

Summary

This phase II trial studies the side effects and how well tivantinib works in treating patients with relapsed, or relapsed and refractory multiple myeloma. Tivantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2011-11

Primary completion

2014-03

Completion

2014-04

Drugs

Indications